'Transplantation Of Human Organs Act, 1994 Requires A Little Amendment

The industry welcomes the recent move of the Government of India, classifying organ preservative solution as 'drug' and bringing it under the Drugs and Cosmetics Act. However, the industry seeks amendment in the Transplantation of Human Organs Act, 1994. Pavan Choudary, DG, Chairman, Medical Technology Association of India (MTAI) informs Usha Sharma that each patient, whose organs are no longer in their optimal state for harvesting can save eight lives through organ donation

Tell us about the market for organ preservative solutions in India as well as globally? What is its current size and by what percentage is it growing?

The global market for organ preservative solution (OPS) is poised to cross $240 million mark by 2021 and is expected to grow at a CAGR of 7.8 per cent. Though America and Europe lead the market for OPS, India is expected to see significant growth as factors, such as multi-organ failures in ageing population, advancement in technology and the ensuing quality through the government’s recent announcement to regulate OPS could lead to a significant increase in the size of the market.

How many players are offering organ preservative solutions in India and for which organs?

We wouldn’t know the exact number of companies that offer OPS. To name a few such companies; Sandor, Dr Franz Kohler, Bristol-Myers Squibb, Krishgen, Waters Medical Systems, Organ Recovery Systems etc. are supplying OPS in India. Currently liver, kidneys, heart, lungs, eyes, pancreas are among the eight commonly preserved organs in India.